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Androgen signaling is critical for proliferation of prostate cancer cells but cannot be fully inhibited by current
androgen deprivation therapies. A study by Xu et al. in this issue of Cancer Cell provides insights into the
complexities of androgen signaling in prostate cancer and suggests avenues to target a subset of
androgen-sensitive genes.Prostate cancer (PCa) is the most
frequently diagnosed cancer and the
second leading cause of cancer-related
death in Western men. Since the recogni-
tion of PCa as an androgen-sensitive
disease in 1941, androgen deprivation
strategies have been the principal treat-
ment option for non-organ-confined PCa
or PCa that recurs after initial surgery or
radiation therapy. Androgen deprivation
therapies (ADTs) target the action of the
androgen receptor (AR), the transcription
factor mediating the cellular effects of
androgens, by reducing the circulating
levelsof itsnatural ligandsand/orbyadmin-
istration of antiandrogens that compete for
binding to the AR. Following initial remis-
sion, most PCas recur after ADT, giving
rise to castration-recurrent PCa (CRPC),
which is almost invariably lethal. Evidence
from basic research and clinical studies
indicates that the AR and AR-dependent
transcriptional program remain activated
in CRPC (Chen et al., 2008; Debes and Tin-
dall, 2004; Mohler, 2008). This unexpected
reactivation of the AR in CRPC, which high-
lights its validity as a therapeutic target also
in CRPC, has been attributed to AR amplifi-
cations, gain-of-function mutations of the
AR,and changes in the activity of regulatorsand signal transduction pathways that
modulate AR activity. More recently, find-
ings of local, intratumoral production of
androgens in CRPC at levels sufficient to
activate the AR have led to therapeutic
approaches targeting in situ androgen
biosynthesis (Attard et al., 2008; Mohler,
2008). While initial results from such clinical
trials are encouraging, they also under-
score the continued reliance of PCa on AR
activation and the resourcefulness of PCa
cells in evading ADT strategies. In-depth
knowledge of the molecular mechanisms
by which the AR regulates transcription of
target genes that are critical to PCa disease
may offer the rationale to design thera-
peutic alternatives targeting this critical
regulator of PCa cell growth.
The AR is a member of the nuclear
receptor superfamily of ligand-activated
transcription factors. Its mechanism of
action resembles that of other members of
the steroid hormone receptor family. In the
classical model of AR action, binding of
androgens causes an inactive cytoplasmic
AR to undergo a change in conformation,
homodimerization, and relocation to the
nucleus. There, the activated AR binds to
specific recognition sequences known as
androgen-responsive elements (AREs)Cancer Clocated in or near androgen-regulated
genes where it recruits the coregulators
and the basal transcriptional machinery
necessary to assemble a productive tran-
scriptional complex and ultimately affect
the transcription of target genes (Heemers
and Tindall, 2007).
Over a decade of screening has identi-
fied approximately 200 proteins that
interact with the AR and collaborate with it
to execute its transcriptional program. At
the same time, systems and bioinformatics
approaches have identified hundreds of
androgen-regulated genes and character-
ized genome-wide AR recruitment sites in
PCa cells. The combined knowledge
gained from these studies is starting to
reveal a picture of daunting complexity
underlying the activity of the AR transcrip-
tional complex that far exceeds the
simplicity of traditional models of androgen
action.
Apart from general transcription factors,
proteins recruited to DNA-bound AR can
be divided into two classes: coregulators
and specific transcription factors that
interact with their consensus binding
elements (Heemers and Tindall, 2007).
The former class consists of proteins that
associate either directly or indirectly withell 15, April 7, 2009 ª2009 Elsevier Inc. 245
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Previewsthe AR to enhance (coactivators) or
repress (corepressors) its transcriptional
activity without themselves necessarily
binding to DNA. Recent efforts at cata-
loguing these regulators reveal a large
number of functionally diverse proteins
involved in a multitude of cellular
processes and pathways, which take
place in different cellular compartments.
These classifications offer a first glance
at the intricate level of protein-protein
interaction associated with generating
the appropriate AR transcriptional output
(Heemers and Tindall, 2007). A significant
proportion of AR-associated coregulators
possess enzymatic properties that are
able to modulate the acetylation, phos-
phorylation, methylation, ubiquitination,
and SUMOylation status of the local
histone environment, as well as that of
the AR itself, several components of the
general transcriptional machinery and
cooperating coregulators (Heemers and
Tindall, 2007). Such modifications have
significant consequences for protein-
protein interactions as well as protein
localization, stability, and turnover and
greatly affect the ability of the local DNA
environment to support active transcrip-
tion. Adding yet another means of control
over the activity of the AR transcriptional
complex, androgens, acting through the
AR, regulate the expression levels of over
a third of the coregulators in PCa cells.
The kinetics and molecular mechanisms
by which androgens exert their effects on
coregulator expression are remarkably
different (Heemers et al., 2009). In addi-
tion, a striking level of AR target gene
specificity is observed among coregula-
tors (Heemers et al., 2009). These obser-
vations suggest that temporal and quanti-
tative changes in the composition of
coregulator complexes exist at AR binding
sites of different target genes.
Additional experimental evidence from
tiling array studies mapping genome-
wide AR recruitment (reviewed in Heemers
and Tindall, 2007; Jia et al., 2008) supports
the concept of a heavily context-depen-
dent composition of the AR transcriptional
complex at target genes. Characterization
of the genomic composition of AR binding
loci shows that they are selectively en-
riched in binding sites for several specific
transcription factors and differ widely in
the localization, composition, and clus-
tering of AREs. Some AR binding sites
appear even completely devoid of246 Cancer Cell 15, April 7, 2009 ª2009 ElsevAR
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igure 1. RNF6-Dependent Ubiquitination of the Androgen Receptor Selectively Regulates
he Expression of a Subset of Target Genes
A) Transcriptional activity of the androgen receptor (AR) at regulatory regions in target genes is mediated by
dynamic interplay between a large cohort of coregulators that function in multiple cellular pathways and
pecific transcription factors (TF) interacting with their cognate binding sites. PIC, preinitiation complex.
B) A new study by Xu et al. (2009) provides evidence that a K6/K27 ubiquitination of the AR by the ubiq-
itin E3 ligase RNF6 selectively regulates the expression of a subset of AR target genes.consensus motifs (50-TGTTCT-30-like)
that are generally accepted to make up
an ARE, suggesting that secondary tran-
scription factors can recruit the AR as
cofactor to convey androgen responsive-
ness over gene expression. The presence
of these transcription factors at AR binding
sites is critical for recruitment of the AR
and RNA polymerase II, affects the recip-
rocal occupancy of these sites by other
transacting factors, and is necessary for
full and timely androgen responsiveness
of the genes in question.
Overall, these observations support the
concept of a selective and dynamic inter-
play between the AR, its associated core-
gulators, and specific transcription factors
at regulatory sites in target genes. More
importantly, they suggest that a better
understanding of the events modulating
the posttranslational modification status
and expression levels of these regulators
may offer novel approaches to more effi-
ciently target AR action for PCa therapy.
The study by Xu et al. (2009) in this issue
of Cancer Cell provides further evidence
to support this hypothesis. The authors
identify RNF6, a ubiquitin E3 ligase, as
an AR-interacting protein and show thatier Inc.RNF6 induces ubiquitination of the
AR. RNF6-dependent AR ubiquitination
is enhanced by androgen treatment,
promotes AR transcriptional activity, and
selectively drives androgen-dependent
expression of a subset of AR target genes.
Key to these events is that RNF6 induces
a K6/K27 polyubiquitination pattern at AR
residues K845 and K847. This topology
and branching pattern of ubiquitin chains
is markedly different from other mono-
or polyubiquitination modifications that
have been described for the AR (Heemers
and Tindall, 2007) and does not decrease
AR stability. Instead, RNF6-dependent
posttranslational modification of the AR
appears to serve as a platform to selec-
tively recruit coactivators such as ARA54
to AREs in the regulatory regions of
a subset of AR target genes (Figure 1).
Importantly, RNF6 is overexpressed in
CRPC, and both RNF6 and K845 AR ubiq-
uitination are critical for PCa growth under
androgen-deprived conditions, indicating
that targeting components of the ubiquiti-
nation machinery may hold promise for
the treatment of CRPC. From a molecular
perspective, the study by Xu et al. thus
highlights the possibility that elucidation
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Previewsof the composition of the AR transcrip-
tional complex, and particularly unravel-
ing of the ‘‘modification codes’’ of its crit-
ical components (e.g., Wu et al., 2004),
may serve as a platform for rational design
of PCa therapies.
REFERENCES
Attard, G., Reid, A.H., Yap, T.A., Raynaud, F.,
Dowsett, M., Settatree, S., Barrett, M., Parker, C.,Glioma Stem Cells
Howard A. Fine1,*
1Center for Cancer Research, Neuro-Oncolog
National Institutes of Health, Bethesda, MD 20
*Correspondence: hfine@mail.nih.gov
DOI 10.1016/j.ccr.2009.03.010
A growing body of evidence sugge
tumorigenic potential. A study by P
stimulate self-renewal and inhibit di
Primary central nervous system (CNS)
malignancies represent an outstanding
model system to explore the cancer stem
cell hypothesis in that tumor- and glioblas-
toma-initiating/stem cells (GICs/GSCs)
have been readily identified in both medul-
loblastomas and glioblastomas (GBMs)
(Hemmati et al., 2003; Singh et al., 2004)
and more is known about the normal devel-
opment of embryonic and adult normal
neural stem cells (NSCs) than any other
tissue-specific stem cell except hemato-
poietic stem cells. In fact, GICs/GSCs have
been shown to have significant similarities
to NSCs through their ability to self-renew,
expression of similar transcriptome pro-
files, and capability of differentiating along
both glial and neuronal lines (Lee et al.,
2006). Comparing the cellular, molecular,
genetic, and epigenetic mechanisms that
underlie basic stem cell properties such
as self-renewal and differentiation should
further elucidate the similarities and differ-
ences between NSCs and GICs/GSCs.
With this as a backdrop, Pen˜uelas et al.
(2009) report in this issue of Cancer Cell
on the effects of transforming growth
factor beta (TGF-b) on GICs/GSCs. TGF-bMartins, V., Folkerd, E., et al. (2008). J. Clin. Oncol.
26, 4563–4571.
Chen, Y., Sawyers, C.L., and Scher, H.I. (2008).
Curr. Opin. Pharmacol. 8, 440–448.
Debes, J.D., and Tindall, D.J. (2004). N. Engl. J.
Med. 351, 1488–1490.
Heemers, H.V., and Tindall, D.J. (2007). Endocr.
Rev. 28, 778–808.
Heemers, H.V., Regan, K.M., Schmidt, L.J., Ander-
son, S.K., Ballman, K.V., and Tindall, D.J. (2009).: Not All Created E
y Branch, National Cancer Institute, National Ins
892, USA
sts that only a small subpopulation o
en˜uelas et al. in this issue of Cancer
fferentiation in a proportion of these
has long been considered a potentially
promising therapeutic target in malignant
gliomas, as much through guilt by associa-
tion as because of clear experimental and/
or clinical evidence (Massague´, 2008). The
overexpression of TGF-b commonly seen
in malignant glioma has been variously
implicated in glioma cell proliferation,
migration, decreased apoptosis, and/or
tumor-specific immunosuppression. In a
new twist, Pen˜uelas and coworkers
demonstrate that TGF-b induces GIC/
GSC self-renewal in vitro and enhanced
tumorigenicity in vivo. TGF-b mediates
this activity through activation of and
subsequent binding of a Smad2/3/4
complex to the promoter region of the
leukemia inhibitory factor (LIF) gene. LIF
then activates the JAK-STAT pathway, as
demonstrated by phosphorylation of
STAT3, leading to increased GIC/GSC
tumorigenesis secondary to their increased
self-renewal and decreased differentiation.
Pen˜uelas et al. find that although LIF
enhances NSC self-renewal and partially
inhibits differentiation, TGF-b in contrast
does not induce LIF expression and thus
has no discernable effect on NSCs.
Cancer CMol. Endocrinol. Published online January 22,
2009. 10.1210/me.2008-0363.
Jia, L., Berman, B.P., Jariwala, U., Yan, X., Cogan,
J.P., Walters, A., Chen, T., Buchanan, G., Frenkel,
B., and Coetzee, G.A. (2008). PLoS ONE 3, e3645.
Mohler,J.L. (2008).Adv.Exp.Med.Biol.617, 223–234.
Wu,R.C.,Qin,J.,Yi,P.,Wong,J.,Tsai,S.Y.,Tsai,M.J.,
and O’Malley, B.W. (2004). Mol. Cell 15, 937–949.
Xu, K., Shimelis, H., Linn, D.E., Jiang, R., Yang, X.,
Sun, F., Guo, Z., Chen, H., Li, W., Chen, H., et al.
(2009). Cancer Cell 15, this issue, 270–282.qual
titute of Neurological Disorders and Stroke,
f malignant glioma cells have true
Cell demonstrates that TGF-b can
glioma-initiating cells.
So does the different response of GICs/
GSCs versus NSCs to TGF-b represent a
corrupted TGF-b signaling pathway, as is
often seen in other epithelial cancers?
Although TGF-b signals through the
Smad2/3/4 complex in both the GICs/
GSCs and NSCs evaluated by Pen˜uelas
et al., it is known that various cofactors
associated with the Smad complex result
in differential gene expression and repres-
sion in a cell context-dependent manner.
It is therefore plausible that a different set
of tumor-related Smad complex-associ-
ated cofactors accounts for the differential
effects of TGF-b induction on the LIF
promoter in GICs/GSCs compared to
NSCs.
Alternately, it is possible that this TGF-
b-mediated pro-self-renewal phenotype
may not be tumor specific but may
rather be representative of normal sig-
naling within a particular NSC subtype not
utilized in the Pen˜uelas et al. study. It is
well known that the effects of TGF-b and
TGF-b family members (BMPs, activins,
inhibins) on CNS development are cell
intrinsic, cell extrinsic, and context depen-
dent. For example, TGF-b inhibits Wnt
ell 15, April 7, 2009 ª2009 Elsevier Inc. 247
